Peripheral Vascular Stents Market: as Abbott’s Esprit BTK becomes the first bioresorbable scaffold cleared for below-the-knee disease on both sides of the Atlantic and Teleflex acquires an entire vascular intervention business specifically to accelerate its own competing resorbable scaffold programme, bioresorbable technology is converting from a single company’s differentiated bet into an industry-wide race, so competitive positioning in the below-the-knee segment increasingly depends on which manufacturer reaches resorbable scaffold scale first rather than on incremental improvement to permanent metallic stent platforms.

The global peripheral vascular stents market size was USD 4.28 Billion in 2025 and is expected to register a revenue CAGR of 7.0% during the forecast period. Market revenue growth is driven by factors such as Abbott’s bioresorbable scaffold technology opening a new therapeutic category for below-the-knee chronic limb-threatening ischaemia treatment, Teleflex’s acquisition of an entire vascular intervention business specifically to accelerate its own resorbable scaffold clinical programme, and continued growth in peripheral artery disease prevalence sustaining structural demand for both permanent and resorbable stent technology. The first driving factor is Abbott’s Esprit BTK bioresorbable scaffold opening an entirely new therapeutic category for below-the-knee disease treatment, extending beyond what permanent metallic stents can offer. Abbott’s Esprit BTK Everolimus-Eluting Resorbable Scaffold received FDA approval in April 2024 and CE Mark approval in August 2025, with two-year LIFE-BTK trial results demonstrating 48% fewer repeat procedures compared to balloon angioplasty, establishing bioresorbable scaffold technology as a clinically superior alternative for below-the-knee chronic limb-threatening ischaemia. The second driving factor is Teleflex’s acquisition of an entire vascular intervention business specifically to accelerate its own competing bioresorbable scaffold clinical development programme. Teleflex completed its acquisition of BIOTRONIK’s Vascular Intervention business for approximately EUR 760 million in July 2025, explicitly citing the opportunity to invest in and expand the clinical trial programme for Freesolve, BIOTRONIK’s sirolimus-eluting resorbable metallic scaffold technology, alongside acquiring an established peripheral and coronary stent portfolio. The third driving factor is continued growth in peripheral artery disease prevalence globally, sustaining structural demand for both permanent metallic and emerging bioresorbable stent technology across the full range of vascular territories. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single manufacturer’s bioresorbable scaffold approval widens its own addressable market as competitors respond not by developing a comparable technology internally from scratch but by acquiring an entire established vascular business specifically to accelerate their own resorbable programme, letting the first mover’s regulatory and clinical validation success trigger acquisition-driven consolidation across the broader competitive field. Once one manufacturer establishes bioresorbable scaffold technology as a clinically superior, regulator-validated category for below-the-knee disease, competitors face a choice between years of independent resorbable technology development or acquiring an already-developing resorbable programme, and Teleflex’s decision to acquire an entire vascular intervention business specifically to gain Freesolve’s resorbable scaffold programme demonstrates that the acquisition path is proving faster than internal development, so first-mover bioresorbable success and acquisition-driven competitive response are directly linked. As a result, demand and revenue share are concentrating around manufacturers with credible bioresorbable scaffold programmes, whether developed internally or acquired, and the forecast tilts toward resorbable technology capturing an increasing share of below-the-knee procedure volume rather than permanent metallic stents maintaining their historical dominance in this specific application. For instance, in July 2025, Teleflex, United States, completed its EUR 760 million acquisition of BIOTRONIK’s Vascular Intervention business specifically to expand its Freesolve sirolimus-eluting resorbable metallic scaffold clinical trial programme, including initiating a US pivotal study, illustrating how bioresorbable scaffold competitive response is driving major acquisition activity across the peripheral vascular stent competitive field. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is Abbott’s Esprit BTK bioresorbable scaffold establishing a genuinely new therapeutic category for below-the-knee chronic limb-threatening ischaemia, distinct from both balloon angioplasty and permanent metallic stenting. A bioresorbable scaffold that dissolves after supporting vessel healing preserves future treatment options for patients who may require repeat intervention, a clinical advantage that no permanent metallic stent can offer, and this fundamental design difference is what has allowed Esprit BTK to demonstrate a 48% reduction in repeat procedures relative to balloon angioplasty, so the technology’s core resorbable design and its clinical outcome advantage are directly linked. Abbott’s Esprit BTK Everolimus-Eluting Resorbable Scaffold received FDA approval in April 2024 and CE Mark approval in August 2025, with two-year LIFE-BTK trial results demonstrating 48% fewer repeat procedures compared to balloon angioplasty, and Abbott subsequently reported positive interim post-approval study data showing a 2.6% composite rate of major adverse limb events and death at 30 days across 200 subjects. The effect on the market is that below-the-knee disease treatment is genuinely shifting toward bioresorbable scaffold technology as the clinically preferred approach for eligible patients, rather than bioresorbable technology remaining a niche alternative to established permanent stenting. These are some of the key factors driving revenue growth of the market.

The second driver is Teleflex’s strategic decision to acquire an entire established vascular intervention business specifically to gain access to a resorbable scaffold clinical programme rather than developing comparable technology independently. Bioresorbable scaffold technology requires years of clinical trial development and regulatory validation, and acquiring a company already several years into that development process compresses a competitor’s time to market relative to starting independent development from scratch, so competitive urgency around bioresorbable technology and acquisition-driven consolidation are directly linked. Teleflex completed its acquisition of BIOTRONIK’s Vascular Intervention business for approximately EUR 760 million in July 2025, gaining an established peripheral stent portfolio including the Dynetic-35 balloon-expandable stent and Pulsar-18 T3 self-expanding stent, while explicitly citing the opportunity to invest in and expand the clinical trial programme for Freesolve, a sirolimus-eluting resorbable metallic scaffold technology, including initiating a US pivotal study. The recent record shows the pace. Teleflex indicated the acquired products would generate EUR 177 million in revenue during the second half of 2025 alone, reflecting the immediate commercial scale the transaction added to its interventional portfolio. The effect on the market is that bioresorbable scaffold competitive response is driving major consolidation activity across the peripheral vascular stent competitive field, converting what could have been years of parallel independent development into accelerated, acquisition-driven competition. These are some of the key factors driving revenue growth of the market.

“Teleflex completed its EUR 760 million acquisition of BIOTRONIK’s Vascular Intervention business in July 2025, explicitly citing the opportunity to expand the clinical trial programme for Freesolve, its sirolimus-eluting resorbable metallic scaffold, demonstrating that acquiring an established resorbable programme is proving faster than independent development in response to Abbott’s Esprit BTK success.”

The third driver is the sustained global growth in peripheral artery disease prevalence, establishing a structural demand base for peripheral vascular stent technology across all applications, not solely the below-the-knee segment where bioresorbable innovation is currently concentrated. More than 50 million Europeans live with peripheral artery disease according to Abbott’s own disclosures, and this scale of underlying disease burden sustains demand for the full range of stent technology, from established permanent metallic stents for superficial femoral and iliac artery disease to emerging bioresorbable scaffolds for below-the-knee applications specifically. The effect on the market is that overall peripheral vascular stent demand growth has a demand floor tied to global peripheral artery disease prevalence, with the specific technology mix within that demand increasingly shifting toward bioresorbable scaffolds in below-the-knee applications. These are some of the key factors driving revenue growth of the market.

However, the peripheral vascular stents market faces adoption constraints from the premium cost of bioresorbable scaffold technology relative to established permanent metallic stents, physician training and technique adaptation requirements, and reimbursement and coverage determination timelines for new bioresorbable technology. Because bioresorbable scaffold technology such as Esprit BTK carries a meaningful cost premium over established permanent metallic stents, reflecting the more sophisticated polymer engineering and drug-elution technology required, hospital and payer cost considerations continue to influence adoption pace even as clinical evidence increasingly favours resorbable technology for below-the-knee applications specifically, and BTIG analysts have noted the need to train interventional centres could result in a gradual rather than immediate launch trajectory. Physician training and technique adaptation is a second constraint, because bioresorbable scaffold deployment and post-procedure management differ meaningfully from established permanent stent technique, and interventionalists require dedicated training and accumulated case experience before achieving the full clinical benefit the technology is capable of delivering, extending the time between regulatory approval and full clinical utilisation at any given centre. Reimbursement and coverage determination timelines are the third constraint, since new bioresorbable scaffold technology requires its own payer coverage determination process independent of established permanent stent reimbursement pathways, and this process takes time to mature across different jurisdictions and payer systems, meaning regulatory approval alone does not guarantee immediate reimbursed patient access at scale. These factors substantially limit peripheral vascular stents market growth over the forecast period.

Based on product type, the global peripheral vascular stents market is segmented into bioresorbable scaffolds, self-expanding metallic stents, and balloon-expandable metallic stents. Self-expanding metallic stents hold the largest revenue share, because they remain the established technology of choice for superficial femoral and iliac artery disease applications, which suits the broad installed base of permanent stent technology across these vascular territories. Bioresorbable scaffolds are expected to register the fastest revenue growth rate in the global peripheral vascular stents market over the forecast period, driven directly by Abbott’s Esprit BTK approval and Teleflex’s Freesolve programme acceleration, which is why this category represents the leading edge of peripheral vascular stent technology investment.

Below-the-knee (BTK) chronic limb-threatening ischaemia application is expected to account for a significantly large revenue share in the global peripheral vascular stents market during the forecast period

Based on application, the global peripheral vascular stents market is segmented into below-the-knee (BTK) chronic limb-threatening ischaemia, superficial femoral artery disease, and iliac artery disease. Below-the-knee chronic limb-threatening ischaemia holds a significant and rapidly growing revenue share, reflecting the concentration of bioresorbable scaffold innovation in this specific application category. Superficial femoral artery disease remains the largest application by overall procedure volume, given the high prevalence of femoropopliteal peripheral artery disease, but below-the-knee applications are capturing a disproportionate share of technology innovation investment.

Polymer (resorbable) material is expected to account for the fastest-growing revenue share in the global peripheral vascular stents market during the forecast period

Based on material, the global peripheral vascular stents market is segmented into polymer (resorbable) and cobalt-chromium/nitinol (permanent) materials. Cobalt-chromium/nitinol (permanent) materials hold the largest current revenue share, reflecting the established, broad installed base of permanent metallic stent technology across all peripheral vascular applications. Polymer (resorbable) material is expected to register the fastest revenue growth rate in the global peripheral vascular stents market over the forecast period, driven directly by both Abbott’s and Teleflex’s bioresorbable scaffold programmes, which is why resorbable polymer technology represents the fastest-evolving material category within the broader market.

Based on regional analysis, the peripheral vascular stents market in North America accounted for largest revenue share in 2025. The United States leads because Abbott’s Esprit BTK received its original FDA approval in the United States before extending to Europe, and because Abbott and Teleflex both concentrate significant commercial and regulatory activity in the country. RBC Capital Markets analysts estimated Esprit BTK’s FDA approval unlocked a USD 400 million addressable United States market specifically, reflecting the scale of commercial opportunity concentrated in the country. The concentration of leading bioresorbable scaffold manufacturers and FDA regulatory activity in the United States also means new peripheral vascular stent technology is typically launched in the United States first.

The market in Europe is expected to register a rapid revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national peripheral vascular stents markets within Europe. Esprit BTK’s August 2025 CE Mark approval extended bioresorbable scaffold availability across the region, addressing a population of more than 50 million Europeans living with peripheral artery disease according to Abbott’s own disclosures. The result is comparatively rapid growth for a mature region, reflecting genuine unmet demand the new bioresorbable category is now addressing.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, and India represent the three largest national peripheral vascular stents markets within the region. Expanding interventional cardiology and vascular surgery infrastructure investment and rising peripheral artery disease prevalence in China and India are driving new stent demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national peripheral vascular stents markets within the region. Interventional vascular centres in both countries are gradually adopting bioresorbable scaffold technology, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised peripheral vascular stents that Latin American vascular centres depend on through 2026, slowing adoption beyond the region’s main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial peripheral vascular stents markets within the GCC. The UAE is the most established peripheral vascular stents market on the continent given its concentrated private hospital interventional vascular infrastructure, while the wider Gulf states and broader African markets are still building the specialist vascular intervention capacity that new stent technology adoption depends on.